Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07424547 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
A Phase 1 study of Breast Cancer and Cancer, sponsored by Conjupro Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 386
- Enrollment target
- 5
- Study locations
NCT07424547 is a Phase 1 study of Breast Cancer and Cancer that is actively recruiting participants, run by Conjupro Biotherapeutics. The registered enrollment target is 386 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT07424547, a Phase 1 study of Breast Cancer and Cancer, is actively recruiting participants, sponsored by Conjupro Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 386 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it. In addition, the study will look for early signs that SYS6043 may help slow or shrink tumors and explore whether the amount of a tumor protein called B7-H3 is related to how well the treatment works. Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive SYS6043 by intravenous infusion once every 3 weeks (Q3W), with 21 days as one treatment cycle until the study doctor determines that study treatment should be stopped based on how well a participant is doing on treatment. * Have safety follow-up (SFU), and long-term follow-up. * Be followed until progression.
Conditions Studied
Interventions
- DRUG SYS6043
Study Locations (5)
Florida
- BRCR Global - Plantation
- Florida Clinical Trials Group - Plantation
Texas
- NEXT Oncology Austin - Austin
- NEXT Oncology San Antonio - San Antonio
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2026-03-03 |
| Est. Completion | 2030-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07424547
The ClinicalTrials.gov registry entry for NCT07424547 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Conjupro Biotherapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which SYS6043 is the first listed.
NCT07424547 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Florida, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT07424547 about?
NCT07424547 is a clinical study titled "Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors". The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause...
What is the current status of trial NCT07424547?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 386 participants. The study started on 2026-03-03. Estimated completion is 2030-04.
What conditions does trial NCT07424547 study?
This clinical trial studies the following conditions: Breast Cancer, Cancer, Ovarian Cancer, Small-cell Lung Cancer, Solid Tumor Cancer.
What interventions are being tested in trial NCT07424547?
The interventions under investigation include: SYS6043 (DRUG).
Who is sponsoring clinical trial NCT07424547?
This trial is sponsored by Conjupro Biotherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07424547 being conducted?
This trial has 5 study locations across Florida, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.